Host: |
HEK293 cells |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human CSF3R/G-CSF-R/CD114-C-His protein was developed from hek293 cells and has a target region of C-His. For use in research applications. |
Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Immunoreactivity: |
Measured by its ability to inhibit the GCSF-induced proliferation of M-NFS-60 mouse myelogenous leukemia lymphoblast cells.The ED50 for this ettect is typically 31.5-126 ng/mL. |
Gene Symbol: |
CSF3R |
Gene ID: |
1441 |
Uniprot ID: |
CSF3R_HUMAN |
Immunogen Region: |
Glu25-Pro621 |
Immunogen: |
Recombinant Human CSF3R/G-CSF-R/CD114 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Glu25-Pro621) of human GCSF Receptor (Accession #NP_000751.1) fused with a 6×His tag at the C-terminus. |
Post Translational Modifications | N-glycosylated. |
Function | Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differientation and survival of cells along the neutrophilic lineage. In addition it may function in some adhesion or recognition events at the cell surface. |
Protein Name | Granulocyte Colony-Stimulating Factor ReceptorG-Csf ReceptorG-Csf-RCd Antigen Cd114 |
Database Links | Reactome: R-HSA-449836Reactome: R-HSA-9616222Reactome: R-HSA-9674555Reactome: R-HSA-9705462 |
Cellular Localisation | Isoform 2: SecretedCell MembraneSingle-Pass Type I Membrane Protein |
Alternative Protein Names | Granulocyte Colony-Stimulating Factor Receptor proteinG-Csf Receptor proteinG-Csf-R proteinCd Antigen Cd114 proteinCSF3R proteinGCSFR protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance